Skip to main content

RT @ericdeinmd: #RNL2023 Year in Review BE COMPLETE: P3 trial Bimekizumab for PsA in TNF inadequate responses at 16 week

Mar 19, 2023 9:24 am
Social Author Name
Eric Dein
Tweet Content
#RNL2023 Year in Review BE COMPLETE: P3 trial Bimekizumab for PsA in TNF inadequate responses at 16 weeks 160 mg BKZ SQ q4w vs PBO ACR50 43%, PBO 7% PASI 1000: BKZ 58.5% vs PBO 4.5% Safety: oral candidiasis: 2.6% BKZ vs PBO 0% @RheumNow https://t.co/bW00Wg6Cnf
Show on Archive Page
On
Display in Search Results
On
PDQ
Off